Be the first to like.

Share

Take Actimmune, developed by Genentech Inc. decades ago. By 2012, sales were fizzling. Then rights to the immune-disorder treatment were acquired by a company backed by private equity. The price climbed, 434 percent in two years, and Actimmune was a hot property. Horizon Pharma Plc snapped it up.

Or consider the old Novartis AG cold-sore cream Denavir, notching a 372 percent gain as it changed hands twice with private equity help. Or Dutoprol, 1,057 percent more expensive after a flip. Or Miacalcin, 3,259 percent higher.

They’re among dozens of drugs bought with private financing in the past six years, according to an analysis of products in a database kept by the software company Connecture Inc. The price often rises, and the drug’s often resold.

… Read More

Image: via Flickr AttributionShare Alike Some rights reserved by 401(K) 2013

Be the first to like.

Share
Bloomberg

Tags: , , , , , , , ,

Leave a Reply